Francica, PaolaPaolaFrancica0000-0003-3611-6403Rottenberg, SvenSvenRottenberg0000-0003-2044-98442025-01-082025-01-082018-12-28https://boris-portal.unibe.ch/handle/20.500.12422/200465Inhibitors of poly(ADP-ribose) polymerase (PARPi) have entered the clinic for the treatment of patients with cancers that lack homology-directed DNA repair, but drug resistance remains a clinical hurdle. Recent advances in the identification of PARPi resistance mechanisms have yielded a better understanding of DNA end protection and the relevance of endogenous poly(ADP-ribose) glycohydrolase, highlighting new vulnerabilities.en500 - Science::570 - Life sciences; biology600 - Technology::610 - Medicine & health600 - Technology::630 - Agriculturearticle10.7892/boris.1275283059328410.1186/s13073-018-0612-8